iiinova — where your digital self keeps evolving

Matthew Baggott

@mattbagg.eurosky.social

1K followers 918 following 136 posts

Scientist, CEO @ Tactogen

Posts Replies Media

Matthew Baggott @mattbagg.eurosky.social · 03/06/2026

RE: [200.461] and [200.454] Publication and access costs.

Requested change: Decline to reimburse large commercial article processing charges and hybrid-journal fees that duplicate a subscription, rather than banning publication costs outright. Continue to allow the low-cost means of dissemination: repository and preprint deposit, data-archiving costs, and fees for nonprofit or society publication, and cap any allowable fee at the actual cost of dissemination. Reconcile §200.461 with the federal immediate-access mandate by allowing the open-access fee in the narrow cases where it is the only compliant route. And state expressly that proprietary research databases and data tools remain allowable, since they have no free substitute and the word “periodicals” should not be read to sweep them in.

000

Matthew Baggott @mattbagg.eurosky.social · 03/06/2026

RE: [200.340] Termination when priorities change.

Requested change: Limit termination to defined causes: noncompliance, fraud, or a documented failure to perform. If the rule retains a “termination for convenience” power, give it the safeguards that make the procurement version fair: reasonable notice, an orderly wind-down, and settlement of termination costs as an entitlement rather than a discretionary allowance weighed against the agency's own interest. And do not allow an award already under way to be terminated solely because priorities have changed.

100

Matthew Baggott @mattbagg.eurosky.social · 03/06/2026

RE: [200.205] Pre-issuance review and the role of merit review.

Requested change: Keep merit review at the center of funding decisions. If a senior-appointee sign-off is retained for accountability, limit it to confirming legality and eligibility against a written, published standard, rather than re-scoring scientific merit. And require a written, reviewable reason for any decision that departs from the merit-review recommendation.

100

Matthew Baggott @mattbagg.eurosky.social · 24/03/2026

I'm analyzing some data collected with an online questionnaire a few years ago. We asked about typical dose and out of 568 responses, only about 2.8% said they typically used under 70 mg. Unclear if what is survey noise or people who don't know what they are taking.

The figure is a bar chart titled “Distribution of reported MDMA doses (all non-missing responses).” Along the horizontal axis, the total MDMA dose per session is shown in milligrams, increasing from about 0 to 1000 mg. The vertical axis shows how many people reported each dose. Most bars cluster tightly between roughly 100 and 250 mg, forming a single tall peak centered around 200 mg where the highest bar reaches just over 120 reports. Counts drop off quickly on either side of this peak: there are smaller numbers of reports between about 50 and 100 mg and between 250 and 350 mg. Only a handful of people report very high doses above 400 mg, with isolated bars around 400, 500, 600, 800, and 1000 mg each representing just a few responses. Overall, the distribution is strongly right-skewed, with most reported sessions in the 100–250 mg range and rare but extreme high-dose outliers.

110

Matthew Baggott @mattbagg.eurosky.social · 22/02/2026

Or we can match AUC but have a much lower Cmax. Using a too simple model (1-compartment PK, 1st-order absorp, tmax = 2.4 h, t½ = 8.4 h; human Cmax/AUC ∝ dose^b with b = 1.12 based on literature Cmaxes), we can get rough ballpark estimates 240 mg or 685 mg to match rat AUC or Cmax, respectively.

Line graph titled "Rat 7.5×3 vs Human Equivalent Exposures." X-axis: Time (0–24 h). Y-axis: Concentration (ng/mL, 0–1600). Three curves are shown. Blue: Rat 7.5 mg/kg x 3 (doses at 0, 2, and 4 h) producing three sharp peaks around ~1100–1500 ng/mL and rapid decline to near zero by ~12 h. Green: Human matched Cmax (686 mg = 9.80 mg/kg) showing a single broad peak near 1500 ng/mL around 3–4 h with slow decline, remaining >300 ng/mL at 24 h. Red: Human matched AUC (241 mg = 3.45 mg/kg) showing a lower single peak around ~450–500 ng/mL near ~2–3 h and gradual decline to about 100 ng/mL at 24 h.

100

Matthew Baggott @mattbagg.eurosky.social · 22/02/2026

Rat regimens that lower 5-HT appear higher than typical human exposures (ignoring for now possible toxic metabolites), see my attached plot. And, in my view, given MDMA's nonlinear PK, we don't have enough PK data on high human exposures to do a great job predicting depleting exposures.

Line graph titled "Simulated Plasma Concentrations." X-axis: Time (0–24 h). Y-axis: MDMA concentration (ng/mL, 0–~1700). Two curves are shown. Black: Human 1.6 mg/kg PO, rising gradually to a single peak around ~250 ng/mL at ~2–3 hours, then declining slowly and remaining above ~50 ng/mL at 24 hours. Red: Rat 7.5 mg/kg IP x 3, with injections at 0, 2, and 4 hours, producing three sharp peaks approximately ~1200, ~1500, and ~1600 ng/mL, followed by rapid decline to near zero by ~12 hours. A black dashed horizontal line marks the rat peak (~1600 ng/mL), and a red dashed horizontal line marks the human peak (~250 ng/mL).

100

Matthew Baggott @mattbagg.eurosky.social · 21/12/2025

One third of SF without power rn pgealerts.alerts.pge.com/outage-tools...

000

Matthew Baggott @mattbagg.eurosky.social · 04/09/2025

Innovative fabrics, relaxed drama, infinite drip. RIP Giorgio Armani.

Two Giorgio Armani ads from 1994. On the left, a couple leans in together wearing relaxed fit light colored clothes in front of a seemingly archeological setting with ancient ruins. On the right, a woman wears a light colored jacket with strong structured shoulders and roomy trousers that drape at the waist and widen dramatically at the hems. She is posed against a minimal background. Both ads emphasize Armani's sophisticated, relaxed tailoring aesthetic.

Two 1994 Giorgio Armani Le Collezioni ads showing two male models in contrasting styles. The left figure wears a minimalist collarless jacket, while the right sports a classic blazer with tie. The sepia-toned photography and relaxed poses against tropical-influenced backgrounds reflect Armani's signature blend of formal and casual elegance.

1989 Giorgio Armani advertising photo showing two models seated together. One wears sunglasses and a light-colored suit jacket, while the other is in a patterned blazer. They're positioned against a white backdrop with a dotted pattern screen behind them.

A 1992 Spring Summer Armani model walks a catwalk in a grey glen plaid suit with a striped tie. The styling is distinctly 1980s or early 1990s, with the model's slicked-back hair and the suit's broad shoulders and relaxed fit, illustrating the generous drape of the power-dressing era of menswear fashion.

130

Matthew Baggott @mattbagg.eurosky.social · 08/07/2025

Here's an early-in-the-meeting slide with FDA examples. Current implementation opportunities seem pretty focused, but it's certainly worth developing more.

010

Matthew Baggott @mattbagg.eurosky.social · 08/07/2025

I'm still watching the video, but the announcement was at the end of the presentation by Nicole Kleinstreuer, PhD, Acting NIH Deputy Director for Program Coordination, Planning, and Strategic Initiatives. Here is the slide.

110